

## Tiiu Noobel

---

**From:** Esindus EL juures üldaadress  
**Sent:** kolmapäev, 10. detsember 2025 11:36  
**To:** Tiiu Noobel  
**Subject:** FW: Estonia - Nomination of a representative to the Executive Steering Group on Shortages of Medical Devices of the European Medicines Agency (EMA)  
**Attachments:** Estonia - MDSSG - Request for nomination.pdf  
**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

---

**From:** MDSSG\_Secretariat <MDSSG\_Secretariat@ema.europa.eu>  
**Sent:** Wednesday, December 10, 2025 11:21 AM  
**To:** Esindus EL juures üldaadress <permrep.eu@mfa.ee>  
**Cc:** Oncan Ece <ece.oncan@ema.europa.eu>  
**Subject:** Estonia - Nomination of a representative to the Executive Steering Group on Shortages of Medical Devices of the European Medicines Agency (EMA)

Your Excellency,

Please find attached a letter signed by the European Medicines Agency's Executive Director requesting the nomination of a representative to the Agency's Executive Steering Group on Shortages of Medical Devices (MDSSG).

The letter is accompanied by an Annex detailing the rules and procedures of the MDSSG. Kindly note that members of the MDSSG will be required to meetings and may have to make decisions on behalf of their Member State in an urgent manner to allow for timely and coordinated actions in the EU. Further information about the MDSSG can be found on the [EMA's website](#).

You are kindly invited to address nominations to the European Medicines Agency's Executive Director Emer Cooke ([Emer.Cooke@ema.europa.eu](mailto:Emer.Cooke@ema.europa.eu)) at your earliest convenience, by **30 January 2026**.

Please do not hesitate to contact us should you have any questions regarding this request for nomination.

Yours sincerely,  
**MDSSG Secretariat**

**Ece Oncan**  
Supply and Availability of Medicines and Devices (SAM)  
Regulatory Science and Innovation Task Force (TRS)



European Medicines Agency  
Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands  
Telephone +31 (0)88 781 6129

Follow us:    

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Classified as confidential by the European Medicines Agency